Metagenomi, Inc. surged -1.29% in after-hours trading, following the release of a macro-genomics market report projecting a 15.4% CAGR from 2024 to 2025, and the company's announcement of successful in vivo mouse concept validation in cardiovascular metabolic diseases with Ionis Pharmaceuticals.
Comments
No comments yet